Dalbavancin in the treatment of skin and soft tissue infections | CMAC

Dalbavancin in the treatment of skin and soft tissue infections

Clinical Microbiology and Antimicrobial Chemotherapy. 2018; 20(4):320-340

Section
Type
Journal article

Abstract

Dalbavancin is a semi-synthetic lipoglycopeptide registered for the treatment of acute bacterial skin and skin structure infections caused by Gram-positive microorganisms, including MRSA. It has a prolonged half-life and excellent tissue levels which allows to its once-weekly administration. Article reviews data of in vitro, in vivo studies and clinical trials results, as well as potential indications of dalbavancin.

Views
0 Abstract
0 PDF
0 Crossref citations
Shared